Decentralising delivery of systemic anti-cancer therapy (SACT) with subcutaneous atezolizumab: service challenges, opportunities and case studies

Elaine Tomlins; Helen Winter; Anna Olsson-Brown; Jenna Robinson; Sally Long; Sarah Sheppard; Caroline Harnett; Sean Dulloo; Samantha Pickering; Joseph Williams

doi:10.12968/bjon.2025.34.Sup10b.S4

Decentralising delivery of systemic anti-cancer therapy (SACT) with subcutaneous atezolizumab: service challenges, opportunities and case studies

Elaine Tomlins
, Helen Winter
, Anna Olsson-Brown
, Jenna Robinson
, Sally Long
, Sarah Sheppard
, Caroline Harnett
, Sean Dulloo
, Samantha Pickering
, Joseph Williams

Cork University Dental School and Hospital

Royal Marsden NHS Foundation Trust
Chair, Transatlantic Studies Association
University Hospitals Bristol and Weston NHS Foundation Trust
Barking, Havering and Redbridge University Hospitals NHS Trust
Peterborough City Hospital
Lead Immunotherapy Senior Nurse Practitioner
University Hospitals of Leicester NHS Trust
Hull University Teaching Hospitals NHS Trust

Research output: Contribution to journal › Article › peer-review

Abstract

Cancer treatment services face considerable pressures across the SACT pathway. The availability of a subcutaneous formulation of Tecentriq (atezolizumab) presents opportunities to decentralise SACT delivery to new treatment venues. With sufficient workforce training and flexibility, decentralisation could produce a lasting improvement in outcomes. Six case studies are presented highlighting successful examples of service decentralisation using subcutaneous (SC) atezolizumab, covering their impacts on patients.

Original language	English
Pages (from-to)	S1-S16
Journal	British Journal of Nursing
Volume	34
Issue number	Sup10b
DOIs	https://doi.org/10.12968/bjon.2025.34.Sup10b.S4
Publication status	Published - 1 May 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Antibodies, Monoclonal, Humanized/administration & dosage
Antineoplastic Agents/administration & dosage
Female
Humans
Injections, Subcutaneous
Neoplasms/drug therapy
United Kingdom

Access to Document

10.12968/bjon.2025.34.Sup10b.S4

Cite this

Tomlins, E., Winter, H., Olsson-Brown, A., Robinson, J., Long, S., Sheppard, S., Harnett, C., Dulloo, S., Pickering, S., & Williams, J. (2025). Decentralising delivery of systemic anti-cancer therapy (SACT) with subcutaneous atezolizumab: service challenges, opportunities and case studies. British Journal of Nursing, 34(Sup10b), S1-S16. https://doi.org/10.12968/bjon.2025.34.Sup10b.S4

@article{12ef4f01b41640908f8d6304e29fe18f,

title = "Decentralising delivery of systemic anti-cancer therapy (SACT) with subcutaneous atezolizumab: service challenges, opportunities and case studies",

abstract = "Cancer treatment services face considerable pressures across the SACT pathway. The availability of a subcutaneous formulation of Tecentriq (atezolizumab) presents opportunities to decentralise SACT delivery to new treatment venues. With sufficient workforce training and flexibility, decentralisation could produce a lasting improvement in outcomes. Six case studies are presented highlighting successful examples of service decentralisation using subcutaneous (SC) atezolizumab, covering their impacts on patients.",

keywords = "Antibodies, Monoclonal, Humanized/administration \& dosage, Antineoplastic Agents/administration \& dosage, Female, Humans, Injections, Subcutaneous, Neoplasms/drug therapy, United Kingdom",

author = "Elaine Tomlins and Helen Winter and Anna Olsson-Brown and Jenna Robinson and Sally Long and Sarah Sheppard and Caroline Harnett and Sean Dulloo and Samantha Pickering and Joseph Williams",

note = "Publisher Copyright: {\textcopyright} 2025 MA Healthcare Ltd.",

year = "2025",

month = may,

day = "1",

doi = "10.12968/bjon.2025.34.Sup10b.S4",

language = "English",

volume = "34",

pages = "S1--S16",

journal = "British Journal of Nursing",

issn = "0966-0461",

publisher = "MA Healthcare Ltd",

number = "Sup10b",

}

Tomlins, E, Winter, H, Olsson-Brown, A, Robinson, J, Long, S, Sheppard, S, Harnett, C, Dulloo, S, Pickering, S & Williams, J 2025, 'Decentralising delivery of systemic anti-cancer therapy (SACT) with subcutaneous atezolizumab: service challenges, opportunities and case studies', British Journal of Nursing, vol. 34, no. Sup10b, pp. S1-S16. https://doi.org/10.12968/bjon.2025.34.Sup10b.S4

TY - JOUR

T1 - Decentralising delivery of systemic anti-cancer therapy (SACT) with subcutaneous atezolizumab

T2 - service challenges, opportunities and case studies

AU - Tomlins, Elaine

AU - Winter, Helen

AU - Olsson-Brown, Anna

AU - Robinson, Jenna

AU - Long, Sally

AU - Sheppard, Sarah

AU - Harnett, Caroline

AU - Dulloo, Sean

AU - Pickering, Samantha

AU - Williams, Joseph

PY - 2025/5/1

Y1 - 2025/5/1

N2 - Cancer treatment services face considerable pressures across the SACT pathway. The availability of a subcutaneous formulation of Tecentriq (atezolizumab) presents opportunities to decentralise SACT delivery to new treatment venues. With sufficient workforce training and flexibility, decentralisation could produce a lasting improvement in outcomes. Six case studies are presented highlighting successful examples of service decentralisation using subcutaneous (SC) atezolizumab, covering their impacts on patients.

AB - Cancer treatment services face considerable pressures across the SACT pathway. The availability of a subcutaneous formulation of Tecentriq (atezolizumab) presents opportunities to decentralise SACT delivery to new treatment venues. With sufficient workforce training and flexibility, decentralisation could produce a lasting improvement in outcomes. Six case studies are presented highlighting successful examples of service decentralisation using subcutaneous (SC) atezolizumab, covering their impacts on patients.

KW - Antibodies, Monoclonal, Humanized/administration & dosage

KW - Antineoplastic Agents/administration & dosage

KW - Female

KW - Humans

KW - Injections, Subcutaneous

KW - Neoplasms/drug therapy

KW - United Kingdom

UR - https://www.scopus.com/pages/publications/105003124658

U2 - 10.12968/bjon.2025.34.Sup10b.S4

DO - 10.12968/bjon.2025.34.Sup10b.S4

M3 - Article

C2 - 40251954

SN - 0966-0461

VL - 34

SP - S1-S16

JO - British Journal of Nursing

JF - British Journal of Nursing

IS - Sup10b

ER -

Decentralising delivery of systemic anti-cancer therapy (SACT) with subcutaneous atezolizumab: service challenges, opportunities and case studies

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this